Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Seattle Genetics receives FDA and EMEA orphan drug designations for SGN-35

Jan. 27, 2009

CTI to begin rolling NDA submission for pixantrone for non-Hodgkin's lymphoma

Jan. 27, 2009

ImClone and Bristol-Myers Squibb withdraw and are to resubmit sBLA for Erbitux

Jan. 27, 2009

Halozyme presents positive preclinical data for PEGPH-20

Jan. 27, 2009

Dual-action inhibitors of Tie2 and KDR kinase prepared and tested at Bayer Schering Pharma

Jan. 27, 2009

Alnylam receives FDA clearance to initiate phase I ALN-VSP study

Jan. 26, 2009

Novel p110alpha inhibitors with anticancer activity developed at Roche

Jan. 26, 2009

The Leukemia & Lymphoma Society and Celator partner for CPX-351 in AML

Jan. 23, 2009

Seattle and FDA reach agreement on SPA for trial of SGN-35 in Hodgkin lymphoma

Jan. 23, 2009

New JAK inhibitors prepared and tested at Merck & Co.

Jan. 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...